iNot medical advice. We don’t recommend any dose. Every dose below is a quote from the person named, describing their views or their own use. Thymosin alpha-1 (thymalfasin, Zadaxin) is approved in a number of countries outside the EU and US, mainly for chronic hepatitis B. It is not FDA-approved and has no central EU authorisation.
8 statements from 7 people. Each one is word for word: we add punctuation only and mark cuts with […]. The chips repeat the exact words used.
“TA1 | 1.6 mg SQ | Twice weekly administration”
Context: SQ means injected under the skin. One row of the “Dosing” table (columns Peptide | Dosing | Comments) in his slides for doctors on autoimmune disease; the table cells are separated here by “|”. The slides are undated.
“HOW I USE THYMOSIN ALPHA-1: 1.5 mg injected subcutaneously once per day if traveling, once per day if recovering from an illness, and every-other-day in normal circumstances (preferably during days where you are training and eating)”
Context: Own use. Just before this he describes injecting it “once a day until we felt better” after he and his wife caught a cold on a flight.
“Thymosin Alpha-1: 1.5 mg injected subcutaneously once per day if traveling, once per day if recovering from an illness, and every other day in normal circumstances.”
Context: Listed in his “Sample Stack for Full Body Optimization”, introduced with “I recommend the following peptide stacks for various purposes”.
“Dosing Guidelines: 1.6 mg per day for 7–10 days. After 10 days, taper to a lower maintenance dose, such as 0.8–1.6 mg 2–3x per week. Best taken in the morning or before bed, on an empty stomach. Administration Route: Subcutaneous injection”
Context: Published as “Dosing Guidelines” in an article on his own site; not described as his own use. Bullet points joined into one passage.
“So generally I tell my patients to use like, uh, 250 micrograms, um, of, uh, thus onha one like once or twice a week, just as, as just, not daily. You can use daily if you're sick, like higher doses […] so I gave her about one, one milligram of thus Alpha One. Next morning she was perfect.”
Context: “thus onha one” and “thus Alpha One” are how the captions render thymosin alpha-1. The second part is about giving his wife a single dose when she was coming down with a cold, around 2016. The drhyman.com transcript labels this turn “Dr. Edwin Lee”.
“We use it a lot with long COVID, and we were using 5,000 micrograms a day, sometimes intravenously, getting great results, very safe, had no issues with it. Unfortunately, it's off the table.”
Context: Describing past use in his clinic for long COVID. “Off the table” refers to US compounding restrictions discussed just before. The non-intravenous route is not stated.
“Doing comes in two protocols. The lower dose range could be more about like a half a milligram daily up to maybe a one and a half milligrams or even higher up to three times per week. Your doctor is going to choose what's best for you based off of your immune system, the conditions, the severity, your autoimmune cases. It's available in either injectable or nasal. In most cases, I notice injections just tend to do better. Cycles can run anywhere from 1 to 3 months.”
Context: “Doing” is how the captions render “Dosing”. The section is about thymosin alpha-1.
“I've used thymosin alpha one when I travel to avoid the cesspool of planes and hotels and all these places, which I would say traveling and then this year on the wards, the first time I don't get flu, cold, whatever kind of infection, I'm dosing thymosin alpha 1 throughout, and I didn't get sick a single time. […] Twice a week, time agnostic. […] We're talking about 2.5 milligrams as a prophylactic. That's not FDA approved or-”
Context: Own use. Andrew Huberman asks “Have you taken thymosin alpha?” and then “What time of day or night are you injecting?”. Huberman adds “This is just you doing your thing”.
1 statement from 1 person about risks and how strong the evidence is.
“thymus in alpha 1 is, uh, proof for infections, it raises that th1, uh, thymus”
Context: Captions are garbled: “thymus in alpha 1” is thymosin alpha-1 and “proof” is probably “approved”. It is approved in some countries outside the EU and US (see the notice above).
Context, not a dosing guide. These are trials in sepsis and hepatitis B. The largest, in sepsis, found no benefit. They are not a guide to immune-boosting use in healthy people.
| Study | Studied in | What the study used | What it found |
|---|---|---|---|
| Wu et al., 2025, BMJ (TESTS)PubMed 39814420 | 1,106 adults with sepsis | Thymosin α1 or placebo every 12 hours for 7 days | 28-day mortality 23.4% vs 24.1%; no benefit |
Yes, in some countries, as Zadaxin, mainly for hepatitis B. Not in the US or through the EU’s central procedure.
No. Thymosin beta-4 (and its fragment TB-500) is a different peptide.
We do not write our own dose ranges. The protocol cards show, word for word, what named people have publicly said, with their caveats and a link to the source.
Word-for-word statements about how thymosin alpha-1 is used for immune support, each with a link to the source. The clinical trials are listed separately as context.
Last reviewed 11 Oct 2026 · Compiled by the Peptide Dosing editorial team · How we check quotes